Insights for oxidative stress and mTOR signaling in myocardial ischemia/reperfusion injury under diabetes

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Zhao, Dajun ^a   Yang, Jian ^a   Yang, Lifang ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Xi'an Gaoxin Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; CELL MEMBRANES; DISEASE CONTROL; DISEASES; FREE RADICALS; NITRIC OXIDE; SIGNALING;

ANTIHYPERGLYCEMIC AGENT; ENDOPLASMIC RETICULUM STRESS; ISCHEMIC HEART DISEASE; NITRIC-OXIDE SYNTHASE; POTENTIAL MECHANISM; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; THERAPEUTIC TARGETS;

OXIDATIVE STRESS;

ANTIOXIDANT; C1Q TNF RELATED PROTEIN 9; COMPLEMENT COMPONENT C1Q; FREE RADICAL; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ADIPONECTIN; ANTIDIABETIC AGENT; C1QTNF9B PROTEIN, HUMAN; GLYCOPROTEIN; MTOR PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

AUTOPHAGY; CARDIOMETABOLIC RISK; CARDIOTOXICITY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; ENDOPLASMIC RETICULUM STRESS; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MITOCHONDRION; MTOR SIGNALING; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; ANIMAL; CHEMISTRY; ENDOPLASMIC RETICULUM; HEART MUSCLE ISCHEMIA; METABOLISM; MOUSE; QUALITY CONTROL; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

DISEASES; METABOLISM; OXIDATION; PATHOLOGY; PHYSIOLOGY;

ADIPONECTIN; ANIMALS; ANTIOXIDANTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOPLASMIC RETICULUM; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; MICE; MITOCHONDRIA; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; QUALITY CONTROL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SIRTUIN 1; TOR SERINE-THREONINE KINASES;

EID: 85015582455     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/6437467     Document Type: Review

References (129)

1. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., "Executive summary: heart disease and stroke statistics-2016 update: a report fromthe American Heart Association, " Circulation, vol. 133, no. 4, pp. 447-454, 2016.
2. A. Zoroufian, T. Razmi, M. Taghavi-Shavazi, M. Lotfi-Tokaldany, and A. Jalali, "Evaluation of subclinical left ventricular dysfunction in diabetic patients: longitudinal strain velocities and left ventricular dyssynchrony by two-dimensional speckle tracking echocardiography study, " Echocardiography, vol. 31, no. 4, pp. 456-463, 2014.
3. N. Hamdani, A.-S. Hervent, L. Vandekerckhove et al., "Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4, " Cardiovascular Research, vol. 104, no. 3, pp. 423-431, 2014.
4. A.M. Shah, S. H. Shin, M. Takeuchi et al., "Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren, " European Journal of Heart Failure, vol. 14, no. 2, pp. 185-192, 2012.
5. N. Frey and E. N. Olson, "Cardiac hypertrophy: the good, the bad, and the ugly, " Annual Review of Physiology, vol. 65, pp. 45- 79, 2003.
6. J. D. Molkentin and G. W. Dorn II, "Cytoplasmic signaling pathways that regulate cardiac hypertrophy, " Annual Review of Physiology, vol. 63, no. 1, pp. 391-426, 2001.
7. N. G. Frangogiannis, "Matricellular proteins in cardiac adaptation and disease, " Physiological Reviews, vol. 92, no. 2, pp. 635- 688, 2012.
8. R. E. Gilbert, "Endothelial loss and repair in the vascular complications of diabetes-mechanisms and therapeutic implications, " Circulation Journal, vol. 77, no. 4, pp. 849-856, 2013.
9. B. M. Everett, M. M. Brooks, H. E.A.Vlachos, B. R. Chaitman, R. L. Frye, and D. L. Bhatt, "Troponin and cardiac events in stable ischemic heart disease and diabetes, " The New England Journal of Medicine, vol. 373, no. 7, pp. 610-620, 2015.
10. C. Emanueli, A. Caporali, N. Krankel, B. Cristofaro, S. Van Linthout, and P. Madeddu, "Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia, " Frontiers in Bioscience, vol. 12, pp. 2003-2012, 2007.
11. M. A. Pfeffer, B. Claggett, R. Diaz et al., "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome, " The New England Journal of Medicine, vol. 373, no. 23, pp. 2247-2257, 2015.
12. H. Suzuki, Y. Kayama, M. Sakamoto et al., "Arachidonate 12/15- lipoxygenase-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy, " Diabetes, vol. 64, no. 2, pp. 618-630, 2015.
13. K. A. Connelly, D. J.Kelly, Y.Zhang et al., "Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat, " Cardiovascular Research, vol. 76, no. 2, pp. 280-291, 2007.
14. M. Rajesh, P. Mukhopadhyay, S. Btkai et al., "Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy, " Journal of the American College of Cardiology, vol. 56, no. 25, pp. 2115-2125, 2010.
15. E. J. Anderson, A. P. Kypson, E. Rodriguez, C. A. Anderson, E. J. Lehr, and P. D. Neufer, "substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart, " Journal of the American College of Cardiology, vol. 54, no. 20, pp. 1891-1898, 2009.
16. E. Braunwald, "Biomarkers in heart failure, " The New England Journal of Medicine, vol. 358, no. 20, pp. 2148-2159, 2008.
17. V. Parra, H. E. Verdejo, M. Iglewski et al., "Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the Akt-mTOR-NFκB-Opa-1 signaling pathway, " Diabetes, vol. 63, no. 1, pp. 75-88, 2014.
18. Y.Matsui, H. Takagi, X. Qu et al., "Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMPactivated protein kinase and beclin 1 in mediating autophagy, " Circulation Research, vol. 100, no. 6, pp. 914-922, 2007.
19. Q. M. Nguyen, S. R. Sinivasan, J.-H. Xu, W. Chen, and G. S. Berenson, "Changes in risk variables of metabolic syndrome since childhood in pre-diabetic and type 2 diabetic subjects.The Bogalusa Heart Study, " Diabetes Care, vol. 31, no. 10, pp. 2044- 2049, 2008.
20. T.Miki, T. Itoh, D. Sunaga, and T.Miura, "Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning, " Cardiovascular Diabetology, vol. 11, article 67, 2012.
21. B. Drenger, I. A. Ostrovsky, M. Barak, Y. Nechemia-Arbely, E. Ziv, and J. H. Axelrod, "Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition, " Anesthesiology-The Journal of the American Society of Anesthesiologists, vol. 114, no. 6, pp. 1364-1372, 2011.
22. P. Ferdinandy, D. J. Hausenloy, G. Heusch, G. F. Baxter, and R. Schulz, "Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning, " Pharmacological reviews, vol. 66, no. 4, pp. 1142- 1174, 2014.
23. D. J.Hausenloy, S. Lecour, andD. M.Yellon, "Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin, " Antioxidants&Redox Signaling, vol. 14, no. 5, pp. 893-907, 2011.
24. N. Ghaboura, S. Tamareille, P.-H. Ducluzeau et al., "Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling, " Basic Research in Cardiology, vol. 106, no. 1, pp. 147-162, 2011.
25. S. Lecour, "Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway?" Journal ofMolecular and Cellular Cardiology, vol. 47, no. 1, pp. 32-40, 2009.
26. C. Zhuo, Y. Wang, X. Wang, Y. Wang, and Y. Chen, "Cardioprotection by ischemic postconditioning is abolished in depressed rats: role ofAkt and signal transducer and activator of transcription-3, " Molecular and Cellular Biochemistry, vol. 346, no. 1-2, pp. 39-47, 2011.
27. W. Yi, Y. Sun, E. Gao et al., "Reduced cardioprotective action of adiponectin in high-fat diet-induced type II diabetic mice and its underlying mechanisms, " Antioxidants & Redox Signaling, vol. 15, no. 7, pp. 1779-1788, 2011.
28. Y. Wang, E. Gao, L. Tao et al., "AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin, " Circulation, vol. 119, no. 6, pp. 835-844, 2009.
29. D. L. Eizirik, A. K. Cardozo, and M. Cnop, "The role for endoplasmic reticulum stress in diabetes mellitus, " Endocrine Reviews, vol. 29, no. 1, pp. 42-61, 2008.
30. L. Yang, D. Zhao, J. Ren, and J. Yang, "Endoplasmic reticulum stress and protein quality control in diabetic cardiomyopathy, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1852, no. 2, pp. 209-218, 2015.
31. T.Miki, T.Miura, H. Hotta et al., "Endoplasmic reticulumstress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3-mediated suppression of mitochondrial permeability transition, " Diabetes, vol. 58, no. 12, pp. 2863-2872, 2009.
32. L. A. Barr, Y. Shimizu, J. P. Lambert, C. K. Nicholson, and J. W. Calvert, "Hydrogen sulfide attenuates high fat diet-induced cardiac dysfunction via the suppression of endoplasmic reticulum stress, " Nitric Oxide, vol. 46, pp. 145-156, 2015.
33. S. Bai, L. Cheng, Y. Yang et al., "C1q/TNF-related protein 9 protects diabetic rat heart against ischemia reperfusion injury: role of endoplasmic reticulum stress, " Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1902025, 14 pages, 2016.
34. M. Aragno, R. Mastrocola, G. Alloatti et al., "Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats, " Endocrinology, vol. 149, no. 1, pp. 380-388, 2008.
35. H. Su, L. Ji, W. Xing et al., "Acute hyperglycaemia enhances oxidative stress and aggravates myocardial ischaemia/reperfusion injury: role of thioredoxin-interacting protein, " Journal of Cellular and Molecular Medicine, vol. 17, no. 1, pp. 181-191, 2013.
36. M. H. Ghattas andD. M.Abo-Elmatty, "Association of polymorphic markers of the catalase and superoxide dismutase genes with type 2 diabetesmellitus, " DNA and Cell Biology, vol. 31, no. 11, pp. 1598-1603, 2012.
37. P. Lewis, N. Stefanovic, J. Pete et al., "Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice, " Circulation, vol. 115, no. 16, pp. 2178-2187, 2007.
38. R. Luan, S. Liu, T. Yin et al., "High glucose sensitizes adult cardiomyocytes to ischaemia/reperfusion injury through nitrative thioredoxin inactivation, " Cardiovascular Research, vol. 83, no. 2, pp. 294-302, 2009.
39. V. Kain, S. Kumar, and S. L. Sitasawad, "Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis, " Cardiovascular Diabetology, vol. 10, article no. 97, 2011.
40. C. Huang, A. M. Andres, E. P. Ratliff, G. Hernandez, P. Lee, and R. A. Gottlieb, "Preconditioning involves selective mitophagy mediated by parkin and p62/SQSTM1, " PLoS ONE, vol. 6, no. 6, Article ID e20975, 2011.
41. A. M. Andres, G. Hernandez, P. Lee et al., "Mitophagy is required for acute cardioprotection by simvastatin, " Antioxidants & Redox Signaling, vol. 21, no. 14, pp. 1960-1973, 2014.
42. S. Kobayashi, X. Xu, K. Chen, and Q. Liang, "Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury, " Autophagy, vol. 8, no. 4, pp. 577-592, 2012.
43. J. Li, S. Rohailla, N.Gelber et al., "MicroRNA-144 is a circulating effector of remote ischemic preconditioning, " Basic Research in Cardiology, vol. 109, no. 5, Article ID 423, 2014.
44. T. Baranyai, C. T. Nagy, G. Koncsos et al., "Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning, " Cardiovascular Diabetology, vol. 14, no. 1, article 151, 2015.
45. K. Raedschelders, D.M. Ansley, and D. D. Y. Chen, "The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion, " Pharmacology andTherapeutics, vol. 133, no. 2, pp. 230-255, 2012.
46. J. L. Carson, P. M. Scholz, A. Y. Chen, E. D. Peterson, J. Gold, and S. H. Schneider, "Diabetes mellitus increases shortterm mortality and morbidity in patients undergoing coronary artery bypass graft surgery, " Journal of the American College of Cardiology, vol. 40, no. 3, pp. 418-423, 2002.
47. X. Du, D. Edelstein, S. Obici, N. Higham, M.-H. Zou, and M. Brownlee, "Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation, "The Journal of Clinical Investigation, vol. 116, no. 4, pp. 1071-1080, 2006.
48. G. Orasanu and J. Plutzky, "The pathologic continuum of diabetic vascular disease, " Journal of the American College of Cardiology, vol. 53, no. 5, pp. S35-S42, 2009.
49. T. Yokota, S. Kinugawa, K. Hirabayashi et al., "Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 297, no. 3, pp. H1069-H1077, 2009.
50. S. Tanguy, J. De Leiris, S. Besse, and F. Boucher, "Ageing exacerbates the cardiotoxicity of hydrogen peroxide through the Fenton reaction in rats, " Mechanisms of Ageing and Development, vol. 124, no. 2, pp. 229-235, 2003.
51. S.-I. Yamagishi, D. Edelstein, X.-L. Du, Y. Kaneda, M. Guzmán, and M. Brownlee, "Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A, " The Journal of Biological Chemistry, vol. 276, no. 27, pp. 25096-25100, 2001.
52. J. Y. Lee, K. H. Sohn, S. H. Rhee, and D. Hwang, "Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4, " Journal of Biological Chemistry, vol. 276, no. 20, pp. 16683- 16689, 2001.
53. N.Coudronniere, M.Villalba, N. Englund, and A. Altman, "NFkappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3394-3399, 2000.
54. R. Ananthakrishnan, M. Kaneko, Y. C. Hwang et al., "Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 2, pp. H333-H341, 2009.
55. W. H. Tang, G. M. Kravtsov, M. Sauert et al., "Polyol pathway impairs the function of SERCAand RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins, " Journal of Molecular and Cellular Cardiology, vol. 49, no. 1, pp. 58-69, 2010.
56. C.-A. Chen, T.-Y. Wang, S. Varadharaj et al., "S-glutathionylation uncouples eNOS and regulates its cellular and vascular function, " Nature, vol. 468, no. 7327, pp. 1115-1118, 2010.
57. R. M.Maalouf, A. A. Eid, Y. C. Gorin et al., "Nox4-derived reactive oxygen speciesmediate cardiomyocyte injury in early type 1 diabetes, " American Journal of Physiology-Cell Physiology, vol. 302, no. 3, pp. C597-C604, 2012.
58. T. Okazaki, H. Otani, T. Shimazu et al., "Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart, " Journal of Molecular and Cellular Cardiology, vol. 50, no. 3, pp. 534-544, 2011.
59. G. Ashrafi and T. L. Schwarz, "The pathways of mitophagy for quality control and clearance of mitochondria, " Cell Death & Differentiation, vol. 20, no. 1, pp. 31-42, 2013.
60. M. P.Murphy, "Induction of mitochondrial ROS production by electrophilic lipids: a new pathway of redox signaling?" American Journal of Physiology-Heart and Circulatory Physiology, vol. 290, no. 5, pp. H1754-H1755, 2006.
61. S.Wullschleger, R. Loewith, and M. N. Hall, "TOR signaling in growth andmetabolism, " Cell, vol. 124, no. 3, pp. 471-484, 2006.
62. S. C. Johnson, P. S. Rabinovitch, and M. Kaeberlein, "MTOR is a key modulator of ageing and age-related disease, " Nature, vol. 493, no. 7432, pp. 338-345, 2013.
63. M. Laplante andD.M. Sabatini, "RegulationofmTORC1 and its impact on gene expression at a glance, " Journal of Cell Science, vol. 126, no. 8, pp. 1713-1719, 2013.
64. D. Zhang, R. Contu, M. V. G. Latronico et al., "MTORC1 regulates cardiac function and myocyte survival through 4EBP1 inhibition in mice, " Journal of Clinical Investigation, vol. 120, no. 10, p. 3735, 2010.
65. M. Laplante and D. M. Sabatini, "MTOR signaling in growth control and disease, " Cell, vol. 149, no. 2, pp. 274-293, 2012.
66. T.Aoyagi, Y. Kusakari, C.-Y. Xiao et al., "CardiacmTORprotects the heart against ischemia-reperfusion injury, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, no. 1, pp. H75-H85, 2012.
67. H. P. Glazer, R. M. Osipov, R. T. Clements, F. W. Sellke, and C. Bianchi, "Hypercholesterolemia is associated with hyperactive cardiacmTORC1 andmTORC2 signaling, " Cell Cycle, vol. 8, no. 11, pp. 1738-1746, 2009.
68. S. C. Land and A. R. Tee, "Hypoxia-inducible factor 1 is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif, " Journal of Biological Chemistry, vol. 282, no. 28, pp. 20534-20543, 2007.
69. J.-W. Park, W.-H. Kim, S.-H. Shin et al., "Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through themTOR signaling pathway, " Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1813, no. 5, pp. 763-771, 2011.
70. P. C. Schenkel, A. M. V. Tavares, R. O. Fernandes et al., "Time course of hydrogen peroxide-thioredoxin balance and its influence on the intracellular signalling in myocardial infarction, " Experimental Physiology, vol. 97, no. 6, pp. 741-749, 2012.
71. A. G. Rajapakse, G. Yepuri, J. M. Carvas et al., "Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: inhibition by resveratrol, " PLoS ONE, vol. 6, no. 4, Article ID e19237, 2011.
72. Z. Z. Chong, Y. C. Shang, and K. Maiese, "Cardiovascular disease and mTOR signaling, " Trends in Cardiovascular Medicine, vol. 21, no. 5, pp. 151-155, 2011.
73. H. Yao, X. Han, and X. Han, "The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway, " American Journal of Cardiovascular Drugs, vol. 14, no. 6, pp. 433-442, 2014.
74. R. Si, L. Tao, H. F. Zhang et al., "Survivin: a novel player in insulin cardioprotection against myocardial ischemia/reperfusion injury, " Journal ofMolecular and Cellular Cardiology, vol. 50, no. 1, pp. 16-24, 2011.
75. V. Lemaître, A. J. Dabo, and J. D'Armiento, "Cigarette smoke components induce matrix metalloproteinase-1 in aortic endothelial cells through inhibition of mTOR signaling, " Toxicological Sciences, vol. 123, no. 2, pp. 542-549, 2011.
76. S. Fourcade, I. Ferrer, andA. Pujol, "Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: a paradigm for axonal degeneration, " Free Radical Biology and Medicine, vol. 88, pp. 18-29, 2015.
77. K.Maiese, Z. Z. Chong, Y. C. Shang, and S.Wang, "Translating cell survival and cell longevity into treatment strategies with SIRT1, " Romanian Journal of Morphology and Embryology, vol. 52, no. 4, pp. 1173-1185, 2011.
78. R.-H. Wang, H.-S. Kim, C. Xiao, X. Xu, O. Gavrilova, and C.- X. Deng, "Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance, "The Journal of Clinical Investigation, vol. 121, no. 11, pp. 4477-4490, 2011.
79. S. C. Ranieri, S. Fusco, E. Panieri et al., "Mammalian lifespan determinant p66shcA mediates obesity-induced insulin resistance, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 30, pp. 13420-13425, 2010.
80. J. C. Drake, S. E. Alway, J. M. Hollander, and D. L.Williamson, "AICAR treatment for 14 days normalizes obesity-induced dysregulation of TORC1 signaling and translational capacity in fasted skeletal muscle, " American Journal of Physiology- Regulatory Integrative and Comparative Physiology, vol. 299, no. 6, pp. R1546-R1554, 2010.
81. S. Turdi, M. R. Kandadi, J. Zhao, A. F. Huff, M. Du, and J. Ren, "Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction, " Journal of Molecular and Cellular Cardiology, vol. 50, no. 4, pp. 712-722, 2011.
82. R. Guo, Y. Zhang, S. Turdi, and J. Ren, "Adiponectin knockout accentuates high fat diet-induced obesity and cardiac dysfunction: role of autophagy, " Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1832, no. 8, pp. 1136-1148, 2013.
83. S. Sciarretta, P. Zhai, D. Shao et al., "Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome, " Circulation, vol. 125, no. 9, pp. 1134-1146, 2012.
84. L. Yang, J.-Y. Gao, J. Ma et al., "Cardiac-specific overexpression of metallothionein attenuates myocardial remodeling and contractile dysfunction in l-NAME-induced experimental hypertension: role of autophagy regulation, " Toxicology Letters, vol. 237, no. 2, pp. 121-132, 2015.
85. C. H. Jung, C. B. Jun, S.-H. Ro et al., "ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery, " Molecular Biology of the Cell, vol. 20, no. 7, pp. 1992-2003, 2009.
86. A. De Waha, A. Dibra, S. Kufner et al., "Long-term outcome after sirolimus-eluting stents versus baremetal stents in patients with Diabetes mellitus: a patient-levelmeta-analysis of randomized trials, " Clinical Research in Cardiology, vol. 100, no. 7, pp. 561-570, 2011.
87. A. Das, F.N. Salloum, D. Durrant, R. Ockaili, and R. C. Kukreja, "Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway, " Journal of Molecular and Cellular Cardiology, vol. 53, no. 6, pp. 858-869, 2012.
88. A.Das, F.N. Salloum, S. M. Filippone et al., "Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling, " Basic Research in Cardiology, vol. 110, no. 3, 2015.
89. T. Aoyagi, J. K. Higa, H. Aoyagi, N. Yorichika, B. K. Shimada, and T. Matsui, "Cardiac mTOR rescues the detrimental effects of diet-induced obesity in the heart after ischemia-reperfusion, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 308, no. 12, pp.H1530-H1539, 2015.
90. M. Zhang, D. Sun, S. Li et al., "Lin28a protects against cardiac ischaemia/reperfusion injury in diabetic mice through the insulin-PI3K-mTOR pathway, " Journal of Cellular and Molecular Medicine, vol. 19, no. 6, pp. 1174-1182, 2015.
91. Z. Lu, X. Xu, X. Hu et al., "PGC-1 regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload, " Antioxidants&Redox Signaling, vol. 13, no. 7, pp. 1011-1022, 2010.
92. J. T. Cunningham, J. T. Rodgers, D. H. Arlow, F. Vazquez, V. K. Mootha, and P. Puigserver, "mTOR controls mitochondrial oxidative function through a YY1-PGC-1 transcriptional complex, " Nature, vol. 450, no. 7170, pp. 736-740, 2007.
93. R. Humar, F. N. Kiefer, H. Berns, T. J. Resink, and E. J. Battegay, "Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling, " FASEB Journal, vol. 16, no. 8, pp. 771-780, 2002.
94. S. G. Miriuka, V. Rao, M. Peterson et al., "mTOR inhibition induces endothelial progenitor cell death, " American Journal of Transplantation, vol. 6, no. 9, pp. 2069-2079, 2006.
95. R. Bernardi, I. Guernah, D. Jin et al., "PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR, " Nature, vol. 442, no. 7104, pp. 779-785, 2006.
96. M. Völkers, M. H. Konstandin, S. Doroudgar et al., "Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage, " Circulation, vol. 128, no. 19, pp. 2132-2144, 2013.
97. C. C. Thoreen and D. M. Sabatini, "Rapamycin inhibits mTORC1, but not completely, " Autophagy, vol. 5, no. 5, pp. 725- 726, 2009.
98. C. Wagner, D. Tillack, G. Simonis, R. H. Strasser, and C. Weinbrenner, "Ischemic post-conditioning reduces infarct size of the in vivo rat heart: role of PI3-K, mTOR, GSK-3β, and apoptosis, "Molecular and Cellular Biochemistry, vol. 339, no. 1-2, pp. 135-147, 2010.
99. R. Pal, M. Palmieri, J. A. Loehr et al., "Src-dependent impairment of autophagy by oxidative stress in a mouse model of Duchenne muscular dystrophy, " Nature Communications, vol. 5, article 4425, 2014.
100. P. Shende, I. Plaisance, C. Morandi et al., "Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice, " Circulation, vol. 123, no. 10, pp. 1073-1082, 2011.
101. P. C. Schenkel, A.M.V. Tavares, R.O. Fernandes et al., "Redoxsensitive prosurvival andproapoptoticprotein expression in the myocardial remodeling post-infarction in rats, " Molecular and Cellular Biochemistry, vol. 341, no. 1-2, pp. 1-8, 2010.
102. E. Martínez-Martínez, R. Jurado-López, M. Valero-Muñoz et al., "Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity, " Journal of Hypertension, vol. 32, no. 5, pp. 1104-1114, 2014.
103. J. Zhang, J. Kim, A. Alexander et al., "A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS, " Nature Cell Biology, vol. 15, no. 10, pp. 1186-1196, 2013.
104. F. Vigneron, P. Dos Santos, S. Lemoine et al., "GSK-3 at the crossroads in the signalling of heart preconditioning: implication ofmTOR andWnt pathways, " Cardiovascular Research, vol. 90, no. 1, pp. 49-56, 2011.
105. S. Sen, B. K. Kundu, H. C.Wu et al., "Glucose regulation of loadinduced mTOR signaling and ER stress in mammalian heart, " Journal of the American Heart Association, vol. 2, no. 3, Article ID e004796, 2013.
106. J. W. Calvert, S. Gundewar, S. Jha et al., "Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS- mediated signaling, " Diabetes, vol. 57, no. 3, pp. 696-705, 2008.
107. X. Xu, Z.Lu, J. Fassett et al., "Metforminprotects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2, " Hypertension, vol. 63, no. 4, pp. 723-728, 2014.
108. M. Hu, P. Ye, H. Liao, M. Chen, and F. Yang, "Metformin protects H9C2 cardiomyocytes from high-glucose and hypoxia/ injury via inhibition of reactive oxygen species generation and inflammatory responses: role of AMPK and JNK, " Journal of Diabetes Research, vol. 2016, Article ID 2961954, 9 pages, 2016.
109. D. Kukidome, T. Nishikawa, K. Sonoda et al., "Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells, " Diabetes, vol. 55, no. 1, pp. 120-127, 2006.
110. X.-F. Wang, J.-Y. Zhang, L. Li, X.-Y. Zhao, H.-L. Tao, and L. Zhang, "Metformin improves cardiac function in rats via activation ofAMP-activated protein kinase, " Clinical and Experimental Pharmacology and Physiology, vol. 38, no. 2, pp. 94-101, 2011.
111. E. P. Daskalopoulos, C. Dufeys, L. Bertrand, C. Beauloye, and S. Horman, "AMPK in cardiac fibrosis and repair: actions beyond metabolic regulation, " Journal ofMolecular and Cellular Cardiology, vol. 91, pp. 188-200, 2016.
112. S.-I. Imai and L. Guarente, "NAD+ and sirtuins in aging and disease, " Trends in Cell Biology, vol. 24, no. 8, pp. 464-471, 2014.
113. G. Donmez and L. Guarente, "Aging and disease: connections to sirtuins, " Aging Cell, vol. 9, no. 2, pp. 285-290, 2010.
114. L. Zhong and R. Mostoslavsky, "Fine tuning our cellular factories: sirtuins in mitochondrial biology, " Cell Metabolism, vol. 13, no. 6, pp. 621-626, 2011.
115. S.-B. Wu, Y.-T. Wu, T.-P. Wu, and Y.-H. Wei, "Role of AMPKmediated adaptive responses in human cellswithmitochondrial dysfunction to oxidative stress, " Biochimica et Biophysica Acta- General Subjects, vol. 1840, no. 4, pp. 1331-1344, 2014.
116. F. Hong, M. D. Larrea, C. Doughty, D. J. Kwiatkowski, R. Squillace, and J. M. Slingerland, "mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation, "Molecular Cell, vol. 30, no. 6, pp. 701-711, 2008.
117. K. Maiese, "Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders, " British Journal of Clinical Pharmacology, vol. 82, no. 5, pp. 1245-1266, 2016.
118. J. M. Peterson, Z. Wei, M. M. Seldin, M. S. Byerly, S. Aja, and G. W. Wong, "CTRP9 transgenic mice are protected from diet-induced obesity and metabolic dysfunction, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 305, no. 5, pp. R522-R533, 2013.
119. Z.Wei, X. Lei, P. S. Petersen, S. Aja, and G.W.Wong, "Targeted deletion of C1q/TNF-related protein 9 increases food intake, decreases insulin sensitivity, and promotes hepatic steatosis in mice, " American Journal of Physiology-Endocrinology and Metabolism, vol. 306, no. 7, pp. E779-E790, 2014.
120. H. Su, Y. Yuan, X.-M.Wang et al., "Inhibition of CTRP9, a novel and cardiac-abundantly expressed cell survival molecule, by TNFα-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice, " Basic Research in Cardiology, vol. 108, no. 1, article no. 315, 2013.
121. T. Kambara, R. Shibata, K. Ohashi et al., "C1q/tumor necrosis factor-related protein 9 protects against acutemyocardial injury through an adiponectin receptor I-AMPK-dependent mechanism, " Molecular and Cellular Biology, vol. 35, no. 12, pp. 2173- 2185, 2015.
122. T. Kambara, K. Ohashi, R. Shibata et al., "CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism, " Journal of Biological Chemistry, vol. 287, no. 23, pp. 18965-18973, 2012.
123. Y. Fang, R. Westbrook, C. Hill et al., "Duration of rapamycin treatment has differential effects on metabolism in mice, " Cell Metabolism, vol. 17, no. 3, pp. 456-462, 2013.
124. V. P. Houde, S. Brûlé, W. T. Festuccia et al., "Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue, " Diabetes, vol. 59, no. 6, pp. 1338- 1348, 2010.
125. L. Yu, C. K.McPhee, L. Zheng et al., "Termination of autophagy and reformation of lysosomes regulated bymTOR, " Nature, vol. 465, no. 7300, pp. 942-946, 2010.
126. Y.-G. Gangloff, M. Mueller, S. G. Dann et al., "Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development, "Molecular and Cellular Biology, vol. 24, no. 21, pp. 9508-9516, 2004.
127. M. Murakami, T. Ichisaka, M. Maeda et al., "mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells, " Molecular and Cellular Biology, vol. 24, no. 15, pp. 6710-6718, 2004.
128. D. A. Guertin, D. M. Stevens, C. C. Thoreen et al., "Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1, " Developmental Cell, vol. 11, no. 6, pp. 859-871, 2006.
129. Y. Rong, C. K. McPhee, S. Deng et al., "Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation, " Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 108, no. 19, pp. 7826- 7831, 2011.